Loading…
Filana Therapeutics, Inc. is projected to rise to $1.42 by 2027, a +20% move from its current price of $1.18. FLNA is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 12 | $1.14 | $1.18 | $1.22 | +0.02% |
| Jul 13 | $1.13 | $1.18 | $1.24 | +0.03% |
| Jul 14 | $1.11 | $1.18 | $1.25 | +0.05% |
| Jul 15 | $1.10 | $1.18 | $1.26 | +0.06% |
| Jul 16 | $1.10 | $1.18 | $1.27 | +0.08% |
| Jul 17 | $1.09 | $1.18 | $1.28 | +0.09% |
| Jul 18 | $1.08 | $1.18 | $1.29 | +0.11% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $1.08 | $1.18 | $1.29 | +0.11% |
| Week 2 | $1.04 | $1.18 | $1.34 | +0.22% |
| Week 3 | $1.01 | $1.18 | $1.38 | +0.32% |
| Week 4 | $0.9919 | $1.19 | $1.42 | +0.43% |
| Week 5 | $0.9723 | $1.19 | $1.45 | +0.54% |
| Week 6 | $0.955 | $1.19 | $1.48 | +0.65% |
| Week 7 | $0.9395 | $1.19 | $1.50 | +0.76% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Filana Therapeutics, Inc. is a clinical stage biotechnology company that develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is in Phase 3 clinical trial to treat Alzheimer's disease; and investigational diagnostic product candidate is SavaDx, an early-stage program focused on detecting the presence of Alzheimer's disease from a small sample of blood.
The company was formerly known as Cassava Sciences, Inc. and changed its name to Filana Therapeutics, Inc. in March 2026. The company was incorporated in 1998 and is based in Austin, Texas.
Filana Therapeutics, Inc. trades as FLNA in the Healthcare space. It currently reports a price of $1.18 per share with a market capitalization of $57M and a rank of 4490. These figures place it among small-cap biotechnology stocks focused on neurodegenerative disease therapies and related diagnostics.
The forecast landscape shows a generally bullish trajectory beyond 2026, with the average price expected to rise from $1.18 in 2026 toward higher levels by 2050. Notably, 2040 and 2050 mid-to-late decade periods imply meaningful upside, with 2040 at an average of $2.84 and 2050 at an average of $4.14, accompanied by substantial projected ROIs.
A major floor 23.2% below — a decisive break under it would weaken the trend.
Price is testing support right now (1.7% away) — a key level to hold.
The nearest ceiling, 31.4% above — a clean break opens room to run.
A major ceiling 101.7% above — clearing it would confirm fresh momentum.
Key FLNA support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of FLNA market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $1.22 | Sell | $1.21 | Sell |
| MA 10 | $1.22 | Sell | $1.22 | Sell |
| MA 20 | $1.22 | Sell | $1.24 | Sell |
| MA 50 | $1.30 | Sell | $1.35 | Sell |
| MA 100 | $1.60 | Sell | $1.58 | Sell |
| MA 200 | $2.23 | Sell | $2.26 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 42.13 | Neutral |
| Stoch RSI (14) | 38.38 | Neutral |
| CCI (20) | -86.34 | Neutral |
| Williams %R (14) | -86.67 | Info |
| MACD (12,26,9) | 0.00 | Buy |
| ROC (12) | -0.84 | Sell |
| Bollinger %B (20,2) | 0.25 | Neutral |
| Stochastic %K (14) | 13.33 | Buy |
| TRIX (15) | -0.46 | Sell |
| Awesome (5,34) | -0.08 | Sell |
| Ultimate (7,14,28) | 45.72 | Neutral |
| Momentum (10) | 0.02 | Buy |
| Aroon Osc (25) | -48.00 | Sell |
| Hull MA (9) | 1.20 | Sell |
| ADX (14) | 16.59 | Neutral |
| ATR (14) | 0.04 | Info |
Near term momentum remains neutral with a cautious setup. The RSI is 40, indicating room to move before oversold conditions occur, while the sentiment is NEUTRAL.
Moving averages show the 50-day at $1.32 and the 200-day at $2.24, suggesting a mixed trend as price action evolves around key levels. Support is noted at $1.16 and resistance at $1.55, framing a tight trading range in the current environment.
The 30-day range spans from a low of $0.9327 to a high of $1.49, and annualized volatility sits at 70%, indicating elevated swings relative to many peers.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.16 | $1.18 | $1.54 | 0% | Neutral | |
| $1.10 | $1.42 | $1.94 | +20% | Bullish | |
| $1.13 | $1.50 | $2.14 | +27% | Bullish | |
| $1.18 | $1.61 | $2.39 | +37% | Bullish | |
| $1.08 | $1.51 | $2.30 | +28% | Bullish | |
| $1.03 | $1.49 | $2.32 | +26% | Bullish | |
| $1.09 | $1.61 | $2.56 | +36% | Bullish | |
| $1.15 | $1.73 | $2.82 | +47% | Bullish | |
| $1.35 | $2.07 | $3.43 | +75% | Bullish | |
| $1.40 | $2.20 | $3.71 | +86% | Bullish | |
| $1.68 | $2.87 | $5.20 | +143% | Bullish | |
| $2.11 | $4.23 | $8.50 | +259% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $1.16 | $1.18 | $1.38 | +0.00% |
| August 2026 | $0.9876 | $1.17 | $1.44 | -0.58% |
| September 2026 | $0.9987 | $1.20 | $1.49 | +2.00% |
| October 2026 | $0.9585 | $1.16 | $1.45 | -3.30% |
| November 2026 | $0.9455 | $1.15 | $1.46 | -0.73% |
| December 2026 | $0.989 | $1.21 | $1.54 | +5.22% |
Click any year to see its month-by-month FLNA forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Filana Therapeutics, Inc.'s 2026 outlook centres on $1.18, within a $1.16 to $1.54 range. That marks a 0% change versus current levels. Price action looks broadly range-bound.
By 2027, FLNA could reach as high as $1.94, with a base case around $1.42 and support toward $1.10 — roughly +20% from $1.18. Buyers look set to stay in control over this stretch.
Expect FLNA to range from $1.13 to $2.14 through 2028. The $1.50 average target implies a +27% move from current prices. That is up +6% on the projected 2027 average. Momentum favours further upside here.
The FLNA price prediction for 2029 points to an average of $1.61 (low $1.18, high $2.39) — a potential gain of +37% on today's $1.18. Buyers look set to stay in control over this stretch.
In 2030, FLNA is projected to trade between $1.08 and $2.30, averaging $1.51 — a potential gain of +28% from today's $1.18. That is -6% versus the projected 2029 average. Momentum favours further upside here.
Filana Therapeutics, Inc.'s 2031 outlook centres on $1.49, within a $1.03 to $2.32 range. That is -2% versus the projected 2030 average. That marks a +26% change versus current levels. Buyers look set to stay in control over this stretch.
By 2032, FLNA could reach as high as $2.56, with a base case around $1.61 and support toward $1.09 — roughly +36% from $1.18. Momentum favours further upside here.
Expect FLNA to range from $1.15 to $2.82 through 2033. The $1.73 average target implies a +47% move from current prices. That is up +8% on the projected 2032 average. Buyers look set to stay in control over this stretch.
The FLNA price prediction for 2034 points to an average of $2.07 (low $1.35, high $3.43) — a potential gain of +75% on today's $1.18. Momentum favours further upside here.
In 2035, FLNA is projected to trade between $1.40 and $3.71, averaging $2.20 — a potential gain of +86% from today's $1.18. That is up +6% on the projected 2034 average. Buyers look set to stay in control over this stretch.
Filana Therapeutics, Inc.'s 2040 outlook centres on $2.87, within a $1.68 to $5.20 range. That is up +31% on the projected 2035 average. That marks a +143% change versus current levels. Momentum favours further upside here.
By 2050, FLNA could reach as high as $8.50, with a base case around $4.23 and support toward $2.11 — roughly +259% from $1.18. Buyers look set to stay in control over this stretch.
Investing $1,000 in FLNA today (≈ 847.457627 FLNA) could be worth
$3,588.04
+$2,588.04 (+259%) by 2050 · US Dollar
Based on the average projected FLNA price of $4.23 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in FLNAwould be worth at today's price.
$1,000 invested in FLNA on Jul 10, 2025 (≈ 462.962945 FLNA) would be worth
$546.3
-$453.7 (-45.4%) today · 0.55× · US Dollar
Based on a FLNA entry price of $2.16 vs. today's $1.18.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $1.23 | $959.35 | -4.1% |
| 1 month ago | $1.32 | $893.94 | -10.6% |
| 3 months ago | $1.64 | $719.51 | -28.0% |
| 6 months ago | $2.12 | $556.6 | -44.3% |
| 1 year ago | $2.16 | $546.3 | -45.4% |
| All time (5.0y) ago | $99.32 | $11.88 | -98.8% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our FLNA forecast.
Our base-case forecast reaches $2.40 around 2040.
Implied market cap at $2.40: $115.94M
The multi-year forecast presents a bullish path across most upcoming years. In 2030, the average price is projected at $1.50 with a min of $1.06 and a max of $2.32, yielding an ROI of 27.5% and a bullish sentiment. This suggests a continued upside despite some near-term volatility.
In 2040, the average price is forecast at $2.84 with a max of $5.27 and an ROI of 140.9%, maintaining a bullish outlook as the company advances its lead programs and diagnostics.
By 2050, the forecast envisions an average price of $4.14 with a max of $8.53 and an ROI of 251.2%, with sentiment remaining BULLISH. These gains reflect the long-range expectation of continued growth in the asset’s value given sustained development activity and market adoption potential.
These projections are estimates, not guarantees, and are subject to clinical, regulatory, and market risks. The volatility highlighted by the 70% annualized volatility metric underscores the potential for substantial price swings and the importance of considering risk alongside any forecast.
Tap a question to reveal the answer.
Avg $1.50; min $1.06; max $2.32; ROI 27.5%; sentiment BULLISH.
Forecasts show a bullish long-term trajectory with an average price of $4.14 by 2050 and an ROI of 251.2%, but these are estimates and not guarantees.
The 2034 forecast shows a max of $3.48, with an average of $2.06 and ROI 74.6%, indicating a possible move near or above $3 in that window.
Current price is $1.18 and market capitalization is $57M.
By 2050 the average forecast price is $4.14 with a max of $8.53 and an ROI of 251.2%, with bullish sentiment.
Filana Therapeutics, Inc. Community Discussion
0Share your Filana Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.